Company: ENTXW
Filing Date: 2025-06-06
Form Type: 424B3
Source: 0001178913-25-002133
Chunk: 4

Company: Entera Bio Ltd.
Filing Date: 2025-06-06
Form: 424B3
Chunk 4
---
 for general corporate purposes, which may include, but are not limited to, research and development costs,                                                 
 including the conduct of one or more clinical trials and process development and manufacturing of our product candidates, potential strategic acquisitions of complementary businesses, services or technologies, expansion of our 
 technology infrastructure and capabilities, working capital, capital expenditures and other general corporate purposes. See “Use of Proceeds.”                                                                                     |
| Risk Factors                                         | You should read the “Risk Factors” section of this prospectus and in our 2024 Annual Report and any updates to those risk factors in our Quarterly Reports on Form 10-Q or subsequent                                              
 Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q incorporated by reference herein, for a discussion of factors to consider carefully before deciding to purchase our ordinary shares.                                |
| Nasdaq Capital Market Symbol                         | Our ordinary shares are listed for trading on Nasdaq under the symbol “ENTX.”                                                                                                                                                      |
| Passive Foreign Investment Company Considerations    | We may be a passive foreign investment company for the current or any other taxable year, which generally would result in adverse U.S. federal income tax consequences to our U.S.                                                 
 investors. See “Risk Factors” beginning on page S-4 for further information.                                                                                                                                                       |

The number of shares to be outstanding after this offering above is based on our actual ordinary shares outstanding as of May 29, 2025 and excludes:

| • | 7,795,198 of our ordinary shares issuable upon the exercise of options outstanding as of March 31, 2025, at a weighted average exercise price of $2.38 per ordinary share; |

| • | 186,936 of our ordinary shares issuable upon the exercise of restricted share units outstanding as of March 31, 2025; |

| • | 1,254,490 of our ordinary shares issuable upon the exercise of pre-funded warrants outstanding as of March 31, 2025; |

| • | 8,344,495 of our ordinary shares issuable upon the exercise of warrants outstanding as of March 31, 2025, at a weighted average exercise price of $1.00 per ordinary share; and |

| • | 3,826,277 of our ordinary shares reserved for future issuance under our 2018 Equity Incentive Plan as of March 31, 2025. |

S-3 RISK FACTORS You should carefully consider the risks and uncertainties described under “Item